VYNE
VYNE Therapeutics Inc (VYNE)
Healthcare • NASDAQ • $0.66-1.92%
- Symbol
- VYNE
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.66
- Daily Change
- -1.92%
- Market Cap
- $22.03M
- Trailing P/E
- N/A
- Forward P/E
- -0.40
- 52W High
- $1.96
- 52W Low
- $0.28
- Analyst Target
- $2.00
- Dividend Yield
- N/A
- Beta
- 2.00
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in S…
Company websiteResearch VYNE on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.